EPISODE · Sep 7, 2023 · 15 MIN
S9 Ep24: FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma
from OncLive® On Air · host OncLive® On Air
Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.
Embed this episode
NOW PLAYING
S9 Ep24: FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma
0:00
15:27
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of OncLive® On Air?
This episode is 15 minutes long.
When was this OncLive® On Air episode published?
This episode was published on September 7, 2023.
Can I download this OncLive® On Air episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!